Skip to main content

Table 5 Subgroup analyses for the relationship between mTOR/p-mTOR expression and OS of patients with ESCC

From: Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Subgroups

N

No. samples

Heterogeneity (I2, p)

Model

HR with 95 % CI

P value

Conclusion

Total

PE

NE

Subgroups stratified by statistical analysis

Multivariate analysis

4

533

283

250

I2 = 26.0 %, p = 0.255

Fixed

2.071 (1.557–2.753)

<0.001

Significant

Univariate analysis

2

180

98

82

I2 = 0.0 %, p = 0.592

Fixed

1.915 (1.114–3.292)

0.019

Significant

Subgroups stratified by cut-off values

10 % staining

3

325

174

151

I2 = 0.0 %, p = 0.731

Fixed

2.577 (1.788–3.714)

<0.001

Significant

Non-10 % staining

3

388

207

181

I2 = 0.0 %, p = 0.694

Fixed

1.644 (1.160–2.328)

0.005

Significant

Subgroups stratified by follow-up periods

≥ 5-year OS

5

565

287

278

I2 = 9.2 %, p = 0.354

Fixed

2.037 (1.542–2.689)

<0.001

Significant

< 5-year OS

1

148

94

54

––––

––––

2.033 (1.117–3.701)

0.020

Significant

Subgroups stratified by positive-staining sites

Cytoplasm

4

473

268

205

I2 = 0.0 %, p = 0.785

Fixed

2.416 (1.769–3.301)

<0.001

Significant

Nucleus or membrane

Given up because of the scarcity of available data

  1. CI confidence interval, ESCC esophageal squamous cell carcinoma, HR hazard ratio, mTOR Mammalian Target of Rapamycin, N reference count, NE negative expression, OS overall survival, PE positive expression, p-mTOR Phosphorylated Mammalian Target of Rapamycin